Premium
Multiple myeloma expressing CD19 + CD56 − phenotype
Author(s) -
Sahara Naohi,
Ihara Michio,
Ono Takaaki,
Tamashima Sadahiro,
Matsui Hirotaka,
Takeshita Akihiro,
Ohno Ryuzo
Publication year - 2000
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/1096-8652(200008)64:4<311::aid-ajh13>3.0.co;2-u
Subject(s) - melphalan , multiple myeloma , bone marrow , lenalidomide , medicine , pancytopenia , immunophenotyping , cancer research , pathology , microbiology and biotechnology , biology , immunology , flow cytometry
A 70‐year‐old woman presented with monoclonal gammopathy, pancytopenia, and renal insufficiency, which were initially refractory to combination chemotherapy by VMMD (vincristine, ranimustine, melphalan, and dexamethasone) and MP (melphalan and prednisolone) regimens. The myeloma cells, which consisted of 73% of bone marrow nucleated cells, expressed CD38 + , CD19 + , CD56 − , CD45 − , CD49e − , and MPC‐1 + phenotypes by flow cytometric analysis and showed the rearranged immunoglobulin heavy chain (IgH) gene by Southern blotting. By immunostaining, the myeloma cells were positive for cytoplasmic immunoglobulin light chain κ. These results suggest that myeloma cells can express CD19 + CD56 − , the phenotype considered to be expressed on only normal plasma cells. Am. J. Hematol. 64:311–313, 2000. © 2000 Wiley‐Liss, Inc.